# Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

> **NCT03873038** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 38 (actual)

## Conditions studied

- Renal Dialysis
- Kidney Failure, Chronic

## Interventions

- **DRUG:** MK-2060
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03873038
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-29
- **Primary completion:** 2021-12-20
- **Final completion:** 2021-12-20
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03873038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03873038, "Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT03873038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*